In India the government has been proactive and supportive in driving the growth of the biotechnology sector by offering grants and tax incentives, and implementing investment-friendly regulations. Companies that do not have plants in Brazil will eventually be eliminated from the market for a particular product. For example, if a company in Brazil decides to build a modern manufacturing plant to produce a product for the local market, the government will buy this product from the company. In particular, government-driven incentive programs are multiplying to encourage local investments in biologics production facilities. In India the number of middle class households (earning between $4,413 and $22,065 a year) is estimated to increase more than four-fold, from $32 million in 2010 to $148 million by 2030.Ĭountries that are growing in size and wealth are looking to establish more domestic industries to support a growing population that can afford to buy more goods and services. In China rapid economic growth and the emergence of a middle class with growing disposable income in the last decade have contributed to an increased demand for high-quality healthcare services. In Brazil alone an estimated 40 million people joined the middle class between 20.
With the improvement of living standards in those countries, the number of patients accessing drug treatments is growing rapidly. The biological drug products market is expanding, especially in emerging economies.
0 kommentar(er)
